Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes.
OBJECTIVE
To assess the association of hot flushes during postmenopause with oxidative stress and to determine whether hormone replacement therapy (HRT) affects the plasma redox status of postmenopausal women.


METHODS
We conducted a prospective clinical study of 49 postmenopausal women who have (n = 29) or do not have (n = 20) hot flushes. Twelve of the postmenopausal women with hot flushes and six without were treated with HRT (estradiol patches and medroxyprogesterone acetate) for 4 months. Plasma level of estradiol, total antioxidant status, reduced sulfhydryl groups, lipoperoxides, total cholesterol, and triglycerides were measured at 4-month intervals in both groups, before and after treatment.


RESULTS
Postmenopausal women who have hot flushes, had lower total basal antioxidant status in plasma (.9 +/-.01 compared with 1.14 +/-.01 mmol/L), lower concentration of reduced sulfhydryl groups (145 +/- 4 compared with 200 +/- 3 micromol/L), and higher concentration of lipoperoxides (2.88 +/-.04 compared with 2.61 +/-.04 micromol/L) than women without hot flushes. After HRT, total antioxidant status and reduced sulfhydryl groups increased, and lipoperoxides decreased similarly in both groups. Hormone replacement therapy decreased the frequency of hot flushes per day from 11.2 +/- 0.8 to 1.4 +/- 0.3.


CONCLUSIONS
Hot flushes in postmenopausal women were associated with the oxidative process. Hormone replacement therapy decreases oxidative stress and the number of episodes of hot flushes. Because oxidative stress is associated with a high risk for cardiovascular diseases, HRT might protect women with hot flushes.
Leal
M
M
Centros de Salud de San Andrés y Beniaján, Murcia, Spain.
Díaz
J
J
Serrano
E
E
Abellán
J
J
Carbonell
L F
LF
D000975:Antioxidants / Q000032:analysis; D004958:Estradiol / Q000097:blood / Q000494:pharmacology; D015914:Estrogen Replacement Therapy; D005260:Female; D019584:Hot Flashes / Q000378:metabolism* / Q000517:prevention & control; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000097:blood / Q000494:pharmacology; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology*; D017698:Postmenopause / Q000502:physiology; D011446:Prospective Studies
D000975:Antioxidants; D004958:Estradiol; D017258:Medroxyprogesterone Acetate